Mentor begins phase 2 study of botulinum toxin type A product for wrinkle treatment

By Angela McDaniels

Seattle, Oct. 27 - Mentor Corp. said it began the phase 2 clinical study of its botulinum toxin type A product, used in the cosmetic treatment of facial wrinkles.

Mentor established its botulinum toxin program through an exclusive licensing agreement with the Wisconsin Alumni Research Foundation in December 2003.

Under terms of the agreement, Mentor obtained the exclusive rights to all strains of the botulinum toxin, including botulinum toxin type A, and has the right to manufacture, develop and commercialize the underlying technology for all indications in all markets, worldwide.

Mentor is based in Santa Barbara, Calif. and develops products for aesthetics and urologic health care markets.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.